Renal Considerations for Beta-Blocker Use

Introduction to Beta-Blocker Pharmacokinetics

Beta-adrenergic blockers (BAAs) vary significantly in their dialyzability based on their pharmacokinetic properties, with some being completely non-dialyzable and requiring careful dosing strategies to prevent toxicity, as noted by the American College of Critical Care 1
Drugs primarily cleared by the liver (e.g., propranolol, carvedilol) generally don't require dose adjustment, whereas drugs primarily cleared by kidneys (e.g., atenolol) require significant dose adjustments, according to the American College of Critical Care 1

For non-dialyzable drugs, increase the dosing interval rather than decreasing the dose to maintain therapeutic peak concentrations, as recommended by the American Thoracic Society 2
Administer medications after dialysis to avoid any potential drug loss during the procedure, as suggested by the American Thoracic Society 2
Carvedilol is the preferred beta-blocker for dialysis patients with heart failure as it's not dialyzable and has shown improved outcomes in this population, although the source of this recommendation is not ideal, it is mentioned by Praxis Medical Insights 3

Watch for bradycardia, hypotension, and other signs of beta-blocker toxicity, as warned by the American College of Critical Care 1
"Rebound" increases in drug concentration can occur after dialysis with many beta-blockers, as noted by the American College of Critical Care 1
Consider withholding certain medications before dialysis if hypotension is problematic, and administer beta-blockers after dialysis when possible, as recommended by Praxis Medical Insights, though not the preferred source, 3